Bristol Myers: Deucravacitinib Shows Superiority to Placebo, Otezla in 2nd Phase 3 Study

By Colin Kellaher

Bristol Myers Squibb Co. on Tuesday said its drug candidate deucravacitinib showed superiority to placebo and to Amgen Inc.'s blockbuster Otezla in a second Phase 3 study in plaque psoriasis.

The New York biopharmaceutical company said superiority of deucravacitinib was shown on both co-primary endpoints and multiple key secondary endpoints in the study of patients with moderate to severe plaque psoriasis.

Bristol Myers, which is studying deucravacitinib in multiple immune-mediated diseases, in November reported that the first Phase 3 study versus placebo and Otezla had met its key endpoints.

Bristol Myers said it plans to discuss the results from both studies with health authorities, "with the goal of offering this novel therapy to those suffering from this serious disease as soon as possible."

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

February 02, 2021 07:48 ET (12:48 GMT)

Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Mar 2024 to Apr 2024